APA (7th ed.) Citation

Subbiah, V., Makker, V., Oh, D., Gardener, E., Gartner, E., & Meric-Bernstam, F. (2025). 1028eTiP DiscovHER PAN-206: Phase II tumour-agnostic study of zanidatamab in patients with previously treated human epidermal growth factor receptor 2 (HER2)-overexpressing solid tumours. Annals of Oncology, 36, S667. https://doi.org/10.1016/j.annonc.2025.08.1597

Chicago Style (17th ed.) Citation

Subbiah, V., V. Makker, D-Y Oh, E. Gardener, E. Gartner, and F. Meric-Bernstam. "1028eTiP DiscovHER PAN-206: Phase II Tumour-agnostic Study of Zanidatamab in Patients with Previously Treated Human Epidermal Growth Factor Receptor 2 (HER2)-overexpressing Solid Tumours." Annals of Oncology 36 (2025): S667. https://doi.org/10.1016/j.annonc.2025.08.1597.

MLA (9th ed.) Citation

Subbiah, V., et al. "1028eTiP DiscovHER PAN-206: Phase II Tumour-agnostic Study of Zanidatamab in Patients with Previously Treated Human Epidermal Growth Factor Receptor 2 (HER2)-overexpressing Solid Tumours." Annals of Oncology, vol. 36, 2025, p. S667, https://doi.org/10.1016/j.annonc.2025.08.1597.